Multidrug treatment for COVID-19.
Identifieur interne : 000325 ( Main/Corpus ); précédent : 000324; suivant : 000326Multidrug treatment for COVID-19.
Auteurs : Masashi Ohe ; Ken Furuya ; Houman GoudarziSource :
- Drug discoveries & therapeutics [ 1881-784X ] ; 2021.
English descriptors
- KwdEn :
- MESH :
- chemical , therapeutic use : Azithromycin, Doxycycline, Hydroxychloroquine, Ivermectin.
- drug therapy : COVID-19.
- methods : Drug Therapy, Combination.
- Drug Repositioning, Humans, Treatment Outcome.
Abstract
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is a process of identifying new therapeutic uses for approved drugs. It is an effective strategy to discover drug molecules with new therapeutic indications. This strategy is time-saving, low-cost, and has a minimal risk of failure. Several existing approved drugs such as chloroquine, hydroxychloroquine, doxycycline, azithromycin, and ivermectin are currently in use because of their efficacy in inhibiting COVID-19. Multidrug therapy, such as a combination of hydroxychloroquine and azithromycin, a combination of doxycycline and ivermectin, or a combination of ivermectin, doxycycline, and azithromycin, has been successfully administered. Multidrug therapy is efficacious because the mechanisms of action of these drugs differ. Moreover, multidrug therapy may prevent the emergence of drug-resistant SARS-CoV-2.
DOI: 10.5582/ddt.2021.01005
PubMed: 33612572
Links to Exploration step
pubmed:33612572Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Multidrug treatment for COVID-19.</title><author><name sortKey="Ohe, Masashi" sort="Ohe, Masashi" uniqKey="Ohe M" first="Masashi" last="Ohe">Masashi Ohe</name><affiliation><nlm:affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Furuya, Ken" sort="Furuya, Ken" uniqKey="Furuya K" first="Ken" last="Furuya">Ken Furuya</name><affiliation><nlm:affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Goudarzi, Houman" sort="Goudarzi, Houman" uniqKey="Goudarzi H" first="Houman" last="Goudarzi">Houman Goudarzi</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:33612572</idno><idno type="pmid">33612572</idno><idno type="doi">10.5582/ddt.2021.01005</idno><idno type="wicri:Area/Main/Corpus">000325</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000325</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Multidrug treatment for COVID-19.</title><author><name sortKey="Ohe, Masashi" sort="Ohe, Masashi" uniqKey="Ohe M" first="Masashi" last="Ohe">Masashi Ohe</name><affiliation><nlm:affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Furuya, Ken" sort="Furuya, Ken" uniqKey="Furuya K" first="Ken" last="Furuya">Ken Furuya</name><affiliation><nlm:affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</nlm:affiliation></affiliation></author><author><name sortKey="Goudarzi, Houman" sort="Goudarzi, Houman" uniqKey="Goudarzi H" first="Houman" last="Goudarzi">Houman Goudarzi</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Drug discoveries & therapeutics</title><idno type="eISSN">1881-784X</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Azithromycin (therapeutic use)</term><term>COVID-19 (drug therapy)</term><term>Doxycycline (therapeutic use)</term><term>Drug Repositioning (MeSH)</term><term>Drug Therapy, Combination (methods)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Ivermectin (therapeutic use)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Azithromycin</term><term>Doxycycline</term><term>Hydroxychloroquine</term><term>Ivermectin</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Drug Therapy, Combination</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Drug Repositioning</term><term>Humans</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is a process of identifying new therapeutic uses for approved drugs. It is an effective strategy to discover drug molecules with new therapeutic indications. This strategy is time-saving, low-cost, and has a minimal risk of failure. Several existing approved drugs such as chloroquine, hydroxychloroquine, doxycycline, azithromycin, and ivermectin are currently in use because of their efficacy in inhibiting COVID-19. Multidrug therapy, such as a combination of hydroxychloroquine and azithromycin, a combination of doxycycline and ivermectin, or a combination of ivermectin, doxycycline, and azithromycin, has been successfully administered. Multidrug therapy is efficacious because the mechanisms of action of these drugs differ. Moreover, multidrug therapy may prevent the emergence of drug-resistant SARS-CoV-2.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33612572</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>17</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1881-784X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Mar</Month><Day>10</Day></PubDate></JournalIssue><Title>Drug discoveries & therapeutics</Title><ISOAbbreviation>Drug Discov Ther</ISOAbbreviation></Journal><ArticleTitle>Multidrug treatment for COVID-19.</ArticleTitle><Pagination><MedlinePgn>39-41</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5582/ddt.2021.01005</ELocationID><Abstract><AbstractText>An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which began in Wuhan, China in December 2019, has rapidly spread all over the world. The World Health Organization characterized the disease caused by SARS-CoV-2 (COVID-19) as a pandemic in March 2020. In the absence of specific treatments for the virus, treatment options are being examined. Drug repurposing is a process of identifying new therapeutic uses for approved drugs. It is an effective strategy to discover drug molecules with new therapeutic indications. This strategy is time-saving, low-cost, and has a minimal risk of failure. Several existing approved drugs such as chloroquine, hydroxychloroquine, doxycycline, azithromycin, and ivermectin are currently in use because of their efficacy in inhibiting COVID-19. Multidrug therapy, such as a combination of hydroxychloroquine and azithromycin, a combination of doxycycline and ivermectin, or a combination of ivermectin, doxycycline, and azithromycin, has been successfully administered. Multidrug therapy is efficacious because the mechanisms of action of these drugs differ. Moreover, multidrug therapy may prevent the emergence of drug-resistant SARS-CoV-2.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ohe</LastName><ForeName>Masashi</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Furuya</LastName><ForeName>Ken</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, JCHO Hokkaido Hospital, Sapporo, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goudarzi</LastName><ForeName>Houman</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Japan</Country><MedlineTA>Drug Discov Ther</MedlineTA><NlmUniqueID>101493809</NlmUniqueID><ISSNLinking>1881-7831</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>70288-86-7</RegistryNumber><NameOfSubstance UI="D007559">Ivermectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>N12000U13O</RegistryNumber><NameOfSubstance UI="D004318">Doxycycline</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004318" MajorTopicYN="N">Doxycycline</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058492" MajorTopicYN="N">Drug Repositioning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007559" MajorTopicYN="N">Ivermectin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">azithromycin</Keyword><Keyword MajorTopicYN="N">doxycycline</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">ivermectin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>22</Day><Hour>5</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33612572</ArticleId><ArticleId IdType="doi">10.5582/ddt.2021.01005</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000325 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000325 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:33612572
|texte= Multidrug treatment for COVID-19.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:33612572" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |